Cambridge Trust CO Akero Therapeutics, Inc. Transaction History
Cambridge Trust CO
- $2.6 Billion
- Q1 2024
A detailed history of Cambridge Trust CO transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Trust CO holds 3,500 shares of AKRO stock, worth $157,955. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,500
Previous 3,500
-0.0%
Holding current value
$157,955
Previous $81,000
8.64%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding AKRO
# of Institutions
210Shares Held
74.3MCall Options Held
321KPut Options Held
558K-
Wellington Management Group LLP Boston, MA7.38MShares$333 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY6.86MShares$310 Million3.11% of portfolio
-
Janus Henderson Group PLC London, X06.03MShares$272 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$252 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$236 Million5.21% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.09B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...